Journal
CURRENT ONCOLOGY REPORTS
Volume 19, Issue 3, Pages -Publisher
SPRINGER
DOI: 10.1007/s11912-017-0578-5
Keywords
Febrile neutropenia; Management; Optimization; Economic evaluation; Biomarker; Patient-reported outcome
Categories
Ask authors/readers for more resources
Febrile neutropenia (FN) is a common and serious complication among cancer patients undergoing myelosuppressive chemotherapy. FN should be treated as a medical emergency because it can lead to life-threatening complications if appropriate treatment is not initiated immediately. This study provides a critical review on the current management of FN and identifies possible directions to optimize FN management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
